Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4982981 | 0.99 | LIMK1 (0.48) | LIMK1SLC6A5KMT2AMEN1RXFP1 | |
| SCHEMBL4976746 | 0.90 | SIGMAR1 (0.47) | LIMK1SLC6A5KMT2AMEN1NPC1 | |
| SCHEMBL1911808 | 0.89 | KMT2A (0.52) | LIMK1KMT2AMEN1RXFP1KDM4E | |
| SCHEMBL1549990 | 0.84 | KMT2A (0.51) | LIMK1SLC6A5KMT2AMEN1KDM4E | |
| SCHEMBL14111444 | 0.83 | LIMK1 (0.49) | LIMK1SLC6A5KMT2AMEN1KDM4E | |
| SCHEMBL4982960 | 0.83 | LIMK1 (0.61) | LIMK1SLC6A5KMT2AMEN1KDM4E | |
| SCHEMBL1898923 | 0.83 | ADORA1 (0.49) | LIMK1SLC6A5KMT2AMEN1RXFP1 | |
| SCHEMBL5772203 | 0.83 | LIMK1 (0.46) | LIMK1SLC6A5KMT2AMEN1KDM4E | |
| SCHEMBL5775686 | 0.83 | SLC6A5 (0.47) | LIMK1SLC6A5KMT2AMEN1KDM4E | |
| SCHEMBL12386805 | 0.82 | P2RX7 (0.50) | LIMK1SLC6A5KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677729-A | AAK1 inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-108431001-B | Fused ring pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2021-09-17 | — | — | CN | disclosed |
| EP-3381916-B1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-04-15 | — | — | EP | disclosed |
| US-10370372-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-06 | — | — | US | disclosed |
| US-10300067-B2 | Tetrahydropyridopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20180312505-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-01 | — | — | US | disclosed |
| EP-3150599-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2018-10-24 | — | — | EP | disclosed |
| EP-3381916-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-03 | — | — | EP | disclosed |
| US-20180161331-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9889136-B2 | Tetrahydropyridopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| WO-2006102610-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | RENOVIS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-6750214-B2 | PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | COLLIS ALAN JOHN (US) | 2004-06-15 | — | — | US | disclosed |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-6642242-B2 | Antiproliferative agents to treat benign prostatic hyperplasia | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
| EP-0877734-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997023462-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | PARK7, UACA, PTGER4 | LIMK1 3676/4885SLC6A5 4875/4885KMT2A 3134/4885 |
| US-20180161331-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | NR5A1, CYP17A1, AR | LIMK1 3253/4885SLC6A5 628/4885KMT2A 1136/4885 |
| US-20180312505-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | AR, NR5A1, FSHR | LIMK1 3074/4885SLC6A5 1780/4885KMT2A 1117/4885 |
| US-10300067-B2 | Tetrahydropyridopyrimidine compound or salt thereof | NR5A1, CYP17A1, DPYD | LIMK1 3588/4885SLC6A5 431/4885KMT2A 1083/4885 |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | LIMK1 3252/4885SLC6A5 2387/4885KMT2A 2003/4885 |
| US-10370372-B2 | Fused pyrimidine compound or salt thereof | AR, NR5A1, FSHR | LIMK1 3074/4885SLC6A5 1780/4885KMT2A 1117/4885 |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, ADRB3 | LIMK1 3292/4885SLC6A5 2298/4885KMT2A 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.